Analyze Diet
British journal of pharmacology2005; 147(1); 23-35; doi: 10.1038/sj.bjp.0706431

Contractile effects of 5-hydroxytryptamine and 5-carboxamidotryptamine in the equine jejunum.

Abstract: The use of human prokinetic drugs in colic horses leads to inconsistent results. This might be related to differences in gastrointestinal receptor populations. The motor effects of 5-hydroxytryptamine (5-HT; serotonin) on the equine mid-jejunum were therefore studied. Longitudinal muscle preparations were set up for isotonic measurement. 5-HT induced tonic contractions with superimposed phasic activity; these responses were not influenced by tetrodotoxin and atropine, suggesting a non-neurogenic, non-cholinergic pathway. The 5-HT receptor antagonists GR 127935 (5-HT(1B,D)), ketanserin (5-HT(2A)), SB 204741 (5-HT(2B)), RS 102221 (5-HT(2C)), granisetron (5-HT(3)), GR 113808 (5-HT(4)) and SB 269970 (5-HT(7)) had no influence on the 5-HT-induced response; the 5-HT(1A) receptor antagonists NAN 190 (pK(b)=8.13+/-0.06) and WAY 100635 (pK(b)=8.69+/-0.07), and the 5-HT(1,2,5,6,7) receptor antagonist methysergide concentration-dependently inhibited the 5-HT-induced contractile response. The 5-HT(1,7) receptor agonist 5-carboxamidotryptamine (5-CT) induced a contractile response similar to that of 5-HT; its effect was not influenced by tetrodotoxin and atropine, and SB 269970, but antagonised by WAY 100635. 8-OHDPAT, buspiron and flesinoxan, which are active at rat and human 5-HT(1A) receptors, had no contractile influence. These results suggest that the contractile effect of 5-HT in equine jejunal longitudinal muscle is due to interaction with muscular 5-HT receptors, which cannot be characterised between the actually known classes of 5-HT receptors.
Publication Date: 2005-10-19 PubMed ID: 16230998PubMed Central: PMC1615837DOI: 10.1038/sj.bjp.0706431Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research examines how serotonin (5-hydroxytryptamine or 5-HT) affects muscle contractions in horse intestines, namely in the jejunum. The study specifically focuses on understanding why common human prokinetic drugs, which boost gastrointestinal activity, show varied effects when used in horses.

Research Methodology

  • The research involved studying the effects of 5-HT on the mid-section of the horse jejunum. The jejunum is part of the small intestine in the equine digestive system.
  • Muscle preparations were created for isotonic measurement. This process allows the measurement of muscle contraction while keeping the pressure constant.
  • To trigger effects, the researchers exposed the muscle preparations to 5-HT. This induced both tonic contractions, which are sustained muscle contractions, and phasic activity, which involves rhythmic, repeated contractions and relaxations.
  • The researchers also observed the effects of various receptor antagonists on the 5-HT responses. These antagonists include GR 127935, ketanserin, SB 204741, RS 102221, granisetron, GR 113808, SB 269970, NAN 190, WAY 100635, and methysergide. They work by blocking specific receptors that interface with 5-HT, effectively reducing or inhibiting its effects.

Results

  • The researchers found that 5-HT-induced responses were not influenced by tetrodotoxin and atropine, suggesting that the action pathway was not connected to the nerve cells (non-neurogenic) or reliant on acetylcholine (non-cholinergic). Tetrodotoxin is a neurotoxin that inhibits nerve signals while atropine is often used to control muscle activities.
  • Most of the receptor antagonists had no influence on the 5-HT-induced response, except for the 5-HT(1A) receptor antagonists NAN 190 and WAY 100635, and the 5-HT(1,2,5,6,7) receptor antagonist methysergide, which inhibited the 5-HT-induced contractile response in a concentration-dependent manner.
  • Similarly, the 5-HT(1,7) receptor agonist 5-carboxamidotryptamine (5-CT), which activates some of the same receptors as 5-HT, triggered a contractile response similar to that of 5-HT, and was not influenced by tetrodotoxin, atropine or SB 269970 but was inhibited by WAY 100635.
  • Some substances that act on rat and human 5-HT(1A) receptors, like 8-OHDPAT, buspiron and flesinoxan, had no impact on the muscle contractions in this study.

Conclusion

The study concludes that the contractile effect of 5-HT in the equine jejunum’s longitudinal muscle mainly results from interaction with muscular 5-HT receptors. The research did not manage to definitively classify these receptors among the currently known classes of 5-HT receptors. Therefore, these results could provide a step towards understanding why human prokinetic drugs have varied effects in horses and might lead to further investigation on the topic in an effort to improve treatment for equine digestive disorders, such as colic.

Cite This Article

APA
Delesalle C, Deprez P, Schuurkes JA, Lefebvre RA. (2005). Contractile effects of 5-hydroxytryptamine and 5-carboxamidotryptamine in the equine jejunum. Br J Pharmacol, 147(1), 23-35. https://doi.org/10.1038/sj.bjp.0706431

Publication

ISSN: 0007-1188
NlmUniqueID: 7502536
Country: England
Language: English
Volume: 147
Issue: 1
Pages: 23-35

Researcher Affiliations

Delesalle, Cathérine
  • Department of Large Animal Internal Medicine, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium. Catherine.Delesalle@UGent.be
Deprez, Piet
    Schuurkes, Jan A J
      Lefebvre, Romain A

        MeSH Terms

        • Animals
        • Dose-Response Relationship, Drug
        • Horses
        • Jejunum / physiology
        • Muscle Contraction / drug effects
        • Serotonin / analogs & derivatives
        • Serotonin / pharmacology
        • Serotonin Agents / pharmacology
        • Serotonin Receptor Agonists / pharmacology

        References

        This article includes 63 references
        1. Ahlers ST, Weissman BA, Barrett JE. Antagonism studies with BMY-7378 and NAN-190: effects on 8-hydroxy-2-(di-n-propylamino)tetralin-induced increases in punished responding of pigeons.. J Pharmacol Exp Ther 1992 Feb;260(2):474-81.
          pubmed: 1531359
        2. Bailey SR, Cunningham FM, Elliott J. Endotoxin and dietary amines may increase plasma 5-hydroxytryptamine in the horse.. Equine Vet J 2000 Nov;32(6):497-504.
          pubmed: 11093623doi: 10.2746/042516400777584730google scholar: lookup
        3. Bailey SR, Marr CM, Elliott J. Identification and quantification of amines in the equine caecum.. Res Vet Sci 2003 Apr;74(2):113-8.
          pubmed: 12589734doi: 10.1016/s0034-5288(02)00175-3google scholar: lookup
        4. Bailey SR, Menzies-Gow NJ, Marr CM, Elliott J. The effects of vasoactive amines found in the equine hindgut on digital blood flow in the normal horse.. Equine Vet J 2004 Apr;36(3):267-72.
          pubmed: 15147136doi: 10.2746/0425164044877297google scholar: lookup
        5. Beer M, Kennett GA, Curzon G. A single dose of 8-OH-DPAT reduces raphe binding of [3H]8-OH-DPAT and increases the effect of raphe stimulation on 5-HT metabolism.. Eur J Pharmacol 1990 Mar 20;178(2):179-87.
          pubmed: 1691712doi: 10.1016/0014-2999(90)90473-jgoogle scholar: lookup
        6. BILL SJ, DOVER GM, RHODES KF. Demonstration of 5-HT1A agonist actions of 5-carboxamidotryptamine in the isolated transmurally stimulated ileum of the guinea-pig.. Br. J. Pharmacol. 1990;100:483.
          pubmed: 0
        7. Bonhaus DW, Weinhardt KK, Taylor M, DeSouza A, McNeeley PM, Szczepanski K, Fontana DJ, Trinh J, Rocha CL, Dawson MW, Flippin LA, Eglen RM. RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist.. Neuropharmacology 1997 Apr-May;36(4-5):621-9.
          pubmed: 9225287doi: 10.1016/s0028-3908(97)00049-xgoogle scholar: lookup
        8. Brianceau P, Chevalier H, Karas A, Court MH, Bassage L, Kirker-Head C, Provost P, Paradis MR. Intravenous lidocaine and small-intestinal size, abdominal fluid, and outcome after colic surgery in horses.. J Vet Intern Med 2002 Nov-Dec;16(6):736-41.
        9. Buchheit KH, Buhl T. Stimulant effects of 5-hydroxytryptamine on guinea pig stomach preparations in vitro.. Eur J Pharmacol 1994 Sep 1;262(1-2):91-7.
          pubmed: 7813582doi: 10.1016/0014-2999(94)90031-0google scholar: lookup
        10. Cao BJ, Rodgers RJ. Influence of 5-HT1A receptor antagonism on plus-maze behaviour in mice. II. WAY 100635, SDZ 216-525 and NAN-190.. Pharmacol Biochem Behav 1997 Oct;58(2):593-603.
          pubmed: 9300624doi: 10.1016/s0091-3057(97)00279-7google scholar: lookup
        11. Chanda PK, Minchin MC, Davis AR, Greenberg L, Reilly Y, McGregor WH, Bhat R, Lubeck MD, Mizutani S, Hung PP. Identification of residues important for ligand binding to the human 5-hydroxytryptamine1A serotonin receptor.. Mol Pharmacol 1993 Apr;43(4):516-20.
          pubmed: 8474430
        12. Cowen DS, Johnson-Farley NN, Travkina T. 5-HT receptors couple to activation of Akt, but not extracellular-regulated kinase (ERK), in cultured hippocampal neurons.. J Neurochem 2005 May;93(4):910-7.
        13. Della Rocca GJ, Mukhin YV, Garnovskaya MN, Daaka Y, Clark GJ, Luttrell LM, Lefkowitz RJ, Raymond JR. Serotonin 5-HT1A receptor-mediated Erk activation requires calcium/calmodulin-dependent receptor endocytosis.. J Biol Chem 1999 Feb 19;274(8):4749-53.
          pubmed: 9988712doi: 10.1074/jbc.274.8.4749google scholar: lookup
        14. Dietrich C, Kilbinger H. 5-HT1A receptor-mediated inhibition of acetylcholine release from guinea pig myenteric plexus: potential mechanisms.. Neuropharmacology 1996 Apr;35(4):483-8.
          pubmed: 8793911doi: 10.1016/0028-3908(95)00197-2google scholar: lookup
        15. Elliott J, Berhane Y, Bailey SR. Effects of monoamines formed in the cecum of horses on equine digital blood vessels and platelets.. Am J Vet Res 2003 Sep;64(9):1124-31.
          pubmed: 13677390doi: 10.2460/ajvr.2003.64.1124google scholar: lookup
        16. Forster EA, Cliffe IA, Bill DJ, Dover GM, Jones D, Reilly Y, Fletcher A. A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635.. Eur J Pharmacol 1995 Jul 25;281(1):81-8.
          pubmed: 8566121doi: 10.1016/0014-2999(95)00234-cgoogle scholar: lookup
        17. Forbes IT, Jones GE, Murphy OE, Holland V, Baxter GS. N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: a novel, high-affinity 5-HT2B receptor antagonist.. J Med Chem 1995 Mar 17;38(6):855-7.
          pubmed: 7699699doi: 10.1021/jm00006a001google scholar: lookup
        18. Forster EA, Cliffe IA, Bill DJ, Dover GM, Jones D, Reilly Y, Fletcher A. A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635.. Eur J Pharmacol 1995 Jul 25;281(1):81-8.
          pubmed: 8566121doi: 10.1016/0014-2999(95)00234-cgoogle scholar: lookup
        19. Galligan JJ. Electrophysiological studies of 5-hydroxytryptamine receptors on enteric neurons.. Behav Brain Res 1996;73(1-2):199-201.
          pubmed: 8788502doi: 10.1016/0166-4328(96)00096-4google scholar: lookup
        20. Galligan JJ, Surprenant A, Tonini M, North RA. Differential localization of 5-HT1 receptors on myenteric and submucosal neurons.. Am J Physiol 1988 Nov;255(5 Pt 1):G603-11.
          pubmed: 2973243doi: 10.1152/ajpgi.1988.255.5.g603google scholar: lookup
        21. Gerring EE, Hunt JM. Pathophysiology of equine postoperative ileus: effect of adrenergic blockade, parasympathetic stimulation and metoclopramide in an experimental model.. Equine Vet J 1986 Jul;18(4):249-55.
        22. GOMMEREN W, RENDERS J, VAN GOMPEL P, LESAGE A, LEYSEN JE, JURZAK MT. Extensive pharmacological study of the G-protein coupled fraction of human 5-HT receptors using agonist radioligand binding.. Naunyn Schmiedebergh's Arch. Pharmacol. 1998;358:8–42.
        23. Guan XM, Peroutka SJ, Kobilka BK. Identification of a single amino acid residue responsible for the binding of a class of beta-adrenergic receptor antagonists to 5-hydroxytryptamine1A receptors.. Mol Pharmacol 1992 Apr;41(4):695-8.
          pubmed: 1349154
        24. Hadrava V, Blier P, Dennis T, Ortemann C, de Montigny C. Characterization of 5-hydroxytryptamine1A properties of flesinoxan: in vivo electrophysiology and hypothermia study.. Neuropharmacology 1995 Oct;34(10):1311-26.
          pubmed: 8570029doi: 10.1016/0028-3908(95)00098-qgoogle scholar: lookup
        25. Hagan JJ, Price GW, Jeffrey P, Deeks NJ, Stean T, Piper D, Smith MI, Upton N, Medhurst AD, Middlemiss DN, Riley GJ, Lovell PJ, Bromidge SM, Thomas DR. Characterization of SB-269970-A, a selective 5-HT(7) receptor antagonist.. Br J Pharmacol 2000 Jun;130(3):539-48.
          pmc: PMC1572114pubmed: 10821781doi: 10.1038/sj.bjp.0703357google scholar: lookup
        26. Hall H, Lundkvist C, Halldin C, Farde L, Pike VW, McCarron JA, Fletcher A, Cliffe IA, Barf T, Wikström H, Sedvall G. Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]way-100635.. Brain Res 1997 Jan 16;745(1-2):96-108.
          pubmed: 9037397doi: 10.1016/s0006-8993(96)01131-6google scholar: lookup
        27. Hensler J, Durgam H. Regulation of 5-HT(1A) receptor-stimulated [35S]-GtpgammaS binding as measured by quantitative autoradiography following chronic agonist administration.. Br J Pharmacol 2001 Jan;132(2):605-11.
          pmc: PMC1572590pubmed: 11159711doi: 10.1038/sj.bjp.0703855google scholar: lookup
        28. Ho BY, Karschin A, Branchek T, Davidson N, Lester HA. The role of conserved aspartate and serine residues in ligand binding and in function of the 5-HT1A receptor: a site-directed mutation study.. FEBS Lett 1992 Nov 9;312(2-3):259-62.
          pubmed: 1426261doi: 10.1016/0014-5793(92)80948-ggoogle scholar: lookup
        29. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).. Pharmacol Rev 1994 Jun;46(2):157-203.
          pubmed: 7938165
        30. Johnson MP, Audia JE, Nissen JS, Nelson DL. N(1)-substituted ergolines and tryptamines show species differences for the agonist-labeled 5-HT2 receptor.. Eur J Pharmacol 1993 Aug 3;239(1-3):111-8.
          pubmed: 8223886doi: 10.1016/0014-2999(93)90983-ogoogle scholar: lookup
        31. Khawaja X, Ennis C, Minchin MC. Pharmacological characterization of recombinant human 5-hydroxytryptamine1A receptors using a novel antagonist radioligand, [3H]WAY-100635.. Life Sci 1997;60(9):653-65.
          pubmed: 9048968doi: 10.1016/s0024-3205(96)00701-1google scholar: lookup
        32. Khawaja X, Evans N, Reilly Y, Ennis C, Minchin MC. Characterisation of the binding of [3H]WAY-100635, a novel 5-hydroxytryptamine1A receptor antagonist, to rat brain.. J Neurochem 1995 Jun;64(6):2716-26.
        33. Kilpatrick AT, Brown CM, MacKinnon AC, Spedding M. The alpha 2-adrenoceptor antagonist SK&F 104078 has high affinity for 5-HT1A and 5-HT2 receptors.. Eur J Pharmacol 1989 Jul 18;166(2):315-8.
          pubmed: 2571511doi: 10.1016/0014-2999(89)90075-7google scholar: lookup
        34. Kirchgessner AL, Liu MT, Howard MJ, Gershon MD. Detection of the 5-HT1A receptor and 5-HT1A receptor mRNA in the rat bowel and pancreas: comparison with 5-HT1P receptors.. J Comp Neurol 1993 Jan 8;327(2):233-50.
          pubmed: 8425944doi: 10.1002/cne.903270206google scholar: lookup
        35. Kirchgessner AL, Liu MT, Raymond JR, Gershon MD. Identification of cells that express 5-hydroxytryptamine1A receptors in the nervous systems of the bowel and pancreas.. J Comp Neurol 1996 Jan 15;364(3):439-455.
        36. Lazareno S, Birdsall NJ. Estimation of antagonist Kb from inhibition curves in functional experiments: alternatives to the Cheng-Prusoff equation.. Trends Pharmacol Sci 1993 Jun;14(6):237-9.
          pubmed: 8372404doi: 10.1016/0165-6147(93)90018-fgoogle scholar: lookup
        37. LePard KJ, Ren J, Galligan JJ. Presynaptic modulation of cholinergic and non-cholinergic fast synaptic transmission in the myenteric plexus of guinea pig ileum.. Neurogastroenterol Motil 2004 Jun;16(3):355-64.
        38. Lippold BS, Hildebrand J, Straub R. Tegaserod (HTF 919) stimulates gut motility in normal horses.. Equine Vet J 2004 Nov;36(7):622-7.
          pubmed: 15581328doi: 10.2746/0425164044864543google scholar: lookup
        39. Menzies-Gow NJ, Bailey SR, Katz LM, Marr CM, Elliott J. Endotoxin-induced digital vasoconstriction in horses: associated changes in plasma concentrations of vasoconstrictor mediators.. Equine Vet J 2004 Apr;36(3):273-8.
          pubmed: 15147137doi: 10.2746/0425164044877260google scholar: lookup
        40. MOLLER M, CUMMING P, ANDERSEN G, GJEDDE A. Parametric mapping of serotonin5HT1Areceptors in healthy humanbrain.. Neuroimage 2004;22:T157.
        41. Morris DD. Endotoxemia in horses. A review of cellular and humoral mediators involved in its pathogenesis.. J Vet Intern Med 1991 May-Jun;5(3):167-81.
        42. Nebigil CG, Garnovskaya MN, Casañas SJ, Mulheron JG, Parker EM, Gettys TW, Raymond JR. Agonist-induced desensitization and phosphorylation of human 5-HT1A receptor expressed in Sf9 insect cells.. Biochemistry 1995 Sep 19;34(37):11954-62.
          pubmed: 7547932doi: 10.1021/bi00037a037google scholar: lookup
        43. Newman-Tancredi A, Verrièle L, Millan MJ. Differential modulation by GTPgammaS of agonist and inverse agonist binding to h5-HT(1A) receptors revealed by [3H]-WAY100,635.. Br J Pharmacol 2001 Jan;132(2):518-24.
          pmc: PMC1572578pubmed: 11159702doi: 10.1038/sj.bjp.0703832google scholar: lookup
        44. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verrièle L, Audinot V, Millan MJ. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.. Eur J Pharmacol 1998 Aug 21;355(2-3):245-56.
          pubmed: 9760039doi: 10.1016/s0014-2999(98)00483-xgoogle scholar: lookup
        45. Nieto JE, Snyder JR, Kollias-Baker C, Stanley S. In vitro effects of 5-hydroxytryptamine and cisapride on the circular smooth muscle of the jejunum of horses.. Am J Vet Res 2000 Dec;61(12):1561-5.
          pubmed: 11131599doi: 10.2460/ajvr.2000.61.1561google scholar: lookup
        46. Pauwels PJ, Van Gompel P, Leysen JE. Activity of serotonin (5-HT) receptor agonists, partial agonists and antagonists at cloned human 5-HT1A receptors that are negatively coupled to adenylate cyclase in permanently transfected HeLa cells.. Biochem Pharmacol 1993 Jan 26;45(2):375-83.
          pubmed: 8382063doi: 10.1016/0006-2952(93)90073-6google scholar: lookup
        47. Pazos A, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors.. Brain Res 1985 Nov 4;346(2):205-30.
          pubmed: 4052776doi: 10.1016/0006-8993(85)90856-xgoogle scholar: lookup
        48. Raymond JR, Mukhin YV, Gettys TW, Garnovskaya MN. The recombinant 5-HT1A receptor: G protein coupling and signalling pathways.. Br J Pharmacol 1999 Aug;127(8):1751-64.
          pmc: PMC1566169pubmed: 10482904doi: 10.1038/sj.bjp.0702723google scholar: lookup
        49. Riad M, Watkins KC, Doucet E, Hamon M, Descarries L. Agonist-induced internalization of serotonin-1a receptors in the dorsal raphe nucleus (autoreceptors) but not hippocampus (heteroreceptors).. J Neurosci 2001 Nov 1;21(21):8378-86.
        50. Rotondo A, Nielsen DA, Nakhai B, Hulihan-Giblin B, Bolos A, Goldman D. Agonist-promoted down-regulation and functional desensitization in two naturally occurring variants of the human serotonin1A receptor.. Neuropsychopharmacology 1997 Jul;17(1):18-26.
          pubmed: 9194046doi: 10.1016/s0893-133x(97)00021-3google scholar: lookup
        51. Roussel AJ Jr, Cohen ND, Hooper RN, Rakestraw PC. Risk factors associated with development of postoperative ileus in horses.. J Am Vet Med Assoc 2001 Jul 1;219(1):72-8.
          pubmed: 11439775doi: 10.2460/javma.2001.219.72google scholar: lookup
        52. Sanger DJ, Schoemaker H. Discriminative stimulus properties of 8-OH-DPAT: relationship to affinity for 5HT1A receptors.. Psychopharmacology (Berl) 1992;108(1-2):85-92.
          pubmed: 1357711doi: 10.1007/bf02245290google scholar: lookup
        53. Sanger GJ, Nelson DR. Selective and functional 5-hydroxytryptamine3 receptor antagonism by BRL 43694 (granisetron).. Eur J Pharmacol 1989 Jan 10;159(2):113-24.
          pubmed: 2540014doi: 10.1016/0014-2999(89)90695-xgoogle scholar: lookup
        54. Serres F, Muma NA, Raap DK, Garcia F, Battaglia G, Van de Kar LD. Coadministration of 5-hydroxytryptamine(1A) antagonist WAY-100635 prevents fluoxetine-induced desensitization of postsynaptic 5-hydroxytryptamine(1A) receptors in hypothalamus.. J Pharmacol Exp Ther 2000 Jul;294(1):296-301.
          pubmed: 10871325
        55. Seth P, Gajendiran M, Ganguly DK. Desensitization of spinal 5-HT1A receptors to 8-OH-DPAT: an in vivo spinal reflex study.. Neuroreport 1997 Jul 28;8(11):2489-93.
        56. Sharif NA, Drace CD, Williams GW, Crider JY. Cloned human 5-HT1A receptor pharmacology determined using agonist binding and measurement of cAMP accumulation.. J Pharm Pharmacol 2004 Oct;56(10):1267-74.
          pubmed: 15482641doi: 10.1211/0022357044346google scholar: lookup
        57. Shirakawa J, Takeda K, Taniyama K, Tanaka C. Dual effects of 5-hydroxytryptamine on the release of gamma-aminobutyric acid from myenteric neurones of the guinea-pig ileum.. Br J Pharmacol 1989 Oct;98(2):339-41.
        58. Snyder JR. The pathophysiology of intestinal damage: effects of luminal distention and ischemia.. Vet Clin North Am Equine Pract 1989 Aug;5(2):247-70.
          pubmed: 2670106doi: 10.1016/s0749-0739(17)30587-4google scholar: lookup
        59. Talley NJ. Serotoninergic neuroenteric modulators.. Lancet 2001 Dec 15;358(9298):2061-8.
          pubmed: 11755632doi: 10.1016/s0140-6736(01)07103-3google scholar: lookup
        60. Terrón JA. GR127935 is a potent antagonist of the 5-HT1-like receptor mediating contraction in the canine coronary artery.. Eur J Pharmacol 1996 Apr 4;300(1-2):109-12.
          pubmed: 8741174doi: 10.1016/0014-2999(96)00041-6google scholar: lookup
        61. Van Hoogmoed LM, Nieto JE, Snyder JR, Harmon FA. Survey of prokinetic use in horses with gastrointestinal injury.. Vet Surg 2004 May-Jun;33(3):279-85.
        62. Vatistas NJ, Nieto JE, Van Hoogmoed L, Gardner I, Snyder JR. Use of an isolated intestinal circuit to evaluate the effect of ischemia and reperfusion on mucosal permeability of the equine jejunum.. Vet Surg 2003 Jan-Feb;32(1):52-61.
          pubmed: 12520490doi: 10.1053/jvet.2003.49999google scholar: lookup
        63. Weiss R, Abel D, Scholtysik G, Straub R, Mevissen M. 5-Hydroxytryptamine mediated contractions in isolated preparations of equine ileum and pelvic flexure: pharmacological characterization of a new 5-HT(4) agonist.. J Vet Pharmacol Ther 2002 Feb;25(1):49-58.

        Citations

        This article has been cited 3 times.
        1. Laus F, Fratini M, Paggi E, Faillace V, Spaterna A, Tesei B, Fettucciari K, Bassotti G. Effects of Single-Dose Prucalopride on Intestinal Hypomotility in Horses: Preliminary Observations. Sci Rep 2017 Jan 27;7:41526.
          doi: 10.1038/srep41526pubmed: 28128322google scholar: lookup
        2. Alberghina D, Giannetto C, Piccione G. Peripheral serotoninergic response to physical exercise in athletic horses. J Vet Sci 2010 Dec;11(4):285-9.
          doi: 10.4142/jvs.2010.11.4.285pubmed: 21113096google scholar: lookup
        3. Prause AS, Stoffel MH, Portier CJ, Mevissen M. Expression and function of 5-HT7 receptors in smooth muscle preparations from equine duodenum, ileum, and pelvic flexure. Res Vet Sci 2009 Oct;87(2):292-9.
          doi: 10.1016/j.rvsc.2009.03.009pubmed: 19364615google scholar: lookup